A centuries-old herbal medicine, discovered by Chinese scientists and used to effectively treat malaria, has been found to potentially aid in the treatment of tuberculosis and may slow the evolution of drug resistance.
In a promising study led by Robert Abramovitch, a Michigan State University microbiologist and TB expert, the ancient remedy artemisinin stopped the ability of TB-causing bacteria, known as Mycobacterium tuberculosis, to become dormant. This stage of the disease often makes the use of antibiotics ineffective.
The study is published in the journal Nature Chemical Biology.
“When TB bacteria are dormant, they become highly tolerant to antibiotics,” Abramovitch said, an assistant professor in the College of Veterinary Medicine. “Blocking dormancy makes the TB bacteria more sensitive to these drugs and could shorten treatment times.”
One-third of the world’s population is infected with TB and the disease killed 1.8 million people in 2015, according to the Centers for Disease Control and Prevention.
Mycobacterium tuberculosis, or Mtb, needs oxygen to thrive in the body. The immune system starves this bacterium of oxygen to control the infection. Abramovitch and his team found that artemisinin attacks a molecule called heme, which is found in the Mtb oxygen sensor. By disrupting this sensor and essentially turning it off, the artemisinin stopped the disease’s ability to sense how much oxygen it was getting.
“When the Mtb is starved of oxygen, it goes into a dormant state, which protects it from the stress of low-oxygen environments,” Abramovitch said. “If Mtb can’t sense low oxygen, then it can’t become dormant and will die.”
Abramovitch indicated that dormant TB can remain inactive for decades in the body. But if the immune system weakens at some point, it can wake back up and spread. Whether it wakes up or stays ‘asleep’ though, he said TB can take up to six months to treat and is one of the main reasons the disease is so difficult to control.
“Patients often don’t stick to the treatment regimen because of the length of time it takes to cure the disease,” he said. “Incomplete therapy plays an important role in the evolution and spread of multi-drug resistant TB strains.”
He said the research could be key to shortening the course of therapy because it can clear out the dormant, hard-to-kill bacteria. This could lead to improving patient outcomes and slowing the evolution of drug-resistant TB.
After screening 540,000 different compounds, Abramovitch also found five other possible chemical inhibitors that target the Mtb oxygen sensor in various ways and could be effective in treatment as well.
“Two billion people worldwide are infected with Mtb,” Abramovitch said. “TB is a global problem that requires new tools to slow its spread and overcome drug resistance. This new method of targeting dormant bacteria is exciting because it shows us a new way to kill it. ”
Learn more: ANCIENT CHINESE MALARIA REMEDY FIGHTS TB
Receive an email update when we add a new TUBERCULOSIS article.
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- Controlling tuberculosis by sniffing in a vaccineon September 7, 2019 at 6:04 am
The disease tuberculosis (TB) has been with us since around 10,000 years ago, when we humans began living in communities. We in India have known it since ancient times, just as the people in Western ...
- Doctor, dubbed S'pore's father of tuberculosis, remembered for saving thousands in new bookon September 7, 2019 at 5:09 am
SINGAPORE - He smuggled medical supplies across enemy lines during the Japanese Occupation, played a pivotal role in eliminating tuberculosis (TB) in Singapore and led the charge against smoking on ...
- Tuberculosis mutation discovery paves way for better treatmentson September 6, 2019 at 12:10 am
A Rutgers New Jersey Medical School study has found a genetically tractable cause of drug tolerant tuberculosis, paving the way for researchers to develop new drugs to combat the global TB ...
- How tuberculosis progresses: genetic factors play a major roleon September 5, 2019 at 2:55 pm
There are almost 1.8 billion people with tuberculosis bacilli in their body, but only about 5% to 15% develop overt infection, usually within 18 months of initial exposure. The reason behind this ...
- Tuberculosis Drugs Market to Surpass US$ 1,651.2 Million by 2027on September 5, 2019 at 12:00 pm
Sep 05, 2019 (IssueWire via COMTEX) -- Seattle, Sep 5, 2019 (Issuewire.com) - Global Tuberculosis Drugs Market, by Therapy Type (First Line Therapy, and Second Line Therapy), By Disease Type (Active ...
- Genome-wide mutational biases fuel transcriptional diversity in the Mycobacterium tuberculosis complexon September 5, 2019 at 2:19 am
The Mycobacterium tuberculosis complex (MTBC) members display different host-specificities and virulence phenotypes. Here, we have performed a comprehensive RNAseq and methylome analysis of the main ...
- A tech intervention to tame tuberculosison September 4, 2019 at 2:02 pm
For tuberculosis patients, complying with a full course of treatment can be daunting and difficult. But a new experiment conducted by MIT researchers in Kenya, in collaboration with the digital ...
- Tuberculosis Diagnostics Market Size and Forecast 2026 | SWOT Analysis, Key Insights and Company Profileson September 4, 2019 at 6:32 am
Sep 04, 2019 (Global QYResearch via COMTEX) -- The global Tuberculosis Diagnostics market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for ...
- Tuberculosis rates down in most U.S. children, but still high in some groupson September 2, 2019 at 1:57 pm
(Reuters Health) - Over the past decade, the number of children and teens in the U.S diagnosed with tuberculosis has decreased by nearly half, according to a new study. But that good news doesn't ...
via Bing News